Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28931677 | 0.85 | TDP1 (0.38) | TDP1TSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL28681494 | 0.82 | PRKCA (0.33) | — | |
| SCHEMBL6887577 | 0.82 | TSHR (0.37) | TDP1TSHRALDH1A1LMNA | |
| SCHEMBL22556010 | 0.80 | PRKCA (0.46) | — | |
| SCHEMBL14972657 | 0.79 | TSHR (0.30) | TSHR | |
| SCHEMBL4488255 | 0.79 | TSHR (0.43) | TDP1TSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL888659 | 0.78 | ALDH1A1 (0.50) | TDP1TSHRALDH1A1LMNAHSD17B10 | |
| SCHEMBL19036036 | 0.78 | — | — | |
| SCHEMBL22556011 | 0.76 | TSHR (0.32) | TSHR | |
| SCHEMBL10662849 | 0.74 | MAPT (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | BCP3 PTY LIMITED (AU) | 2023-11-09 | — | — | US | disclosed |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | BCP3 PTY LIMITED (AU) | 2023-11-09 | — | — | US | disclosed |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | BCP3 PTY LIMITED (AU) | 2023-11-09 | — | — | US | disclosed |
| US-11634411-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2023-04-25 | — | — | US | disclosed |
| EP-3955926-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-02-23 | — | — | EP | disclosed |
| US-20210107899-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2021-04-15 | — | — | US | disclosed |
| US-20210107899-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2021-04-15 | — | — | US | disclosed |
| US-10875845-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2020-12-29 | — | — | US | disclosed |
| US-10875845-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2020-12-29 | — | — | US | disclosed |
| US-20200331896-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2020-10-22 | — | — | US | disclosed |
| WO-2020212755-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212755-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2020-10-22 | — | — | WO | disclosed |
| US-20200331896-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107899-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MUC1, MPO, SERPINB1 | TDP1 2141/4885TSHR 1561/4885ALDH1A1 489/4885 |
| US-20200331896-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MUC1, MPO, SERPINB1 | TDP1 2141/4885TSHR 1561/4885ALDH1A1 489/4885 |
| US-11634411-B2 | Compounds and methods for the treatment of ocular disorders | MUC1, MPO, SERPINB1 | TDP1 2141/4885TSHR 1561/4885ALDH1A1 489/4885 |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MUC1, MPO, SERPINB1 | TDP1 2141/4885TSHR 1561/4885ALDH1A1 489/4885 |
| US-10875845-B2 | Compounds and methods for the treatment of ocular disorders | MUC1, MPO, SERPINB1 | TDP1 2141/4885TSHR 1561/4885ALDH1A1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.